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Objective
The epidermal growth factor receptor (EGFR) gene is
most frequently amplified and overexpressed, along with
its truncated mutant, EGFRvIII, in glioblastomas. We
tested the antitumor efficacy of the recombinant immuno-
toxin, D2C7-(scdsFv)-PE38KDEL (D2C7-IT), which is
reactive with a 55-amino acid (AA) region present in the
extracellular domain of both EGFRwt and EGFRvIII
proteins (Figure 1), by convection-enhanced delivery
(CED) in orthotopic brain tumor mouse models estab-
lished with human glioblastoma xenograft cells.
Methods
Orthotopic brain tumor models were established by inocu-
lating 43 (EGFRwt expressing glioma cell), D270MG
(EGFRwt and EGFRvIII espressing glioma cells), and
NR6M (EGFRvIII expressing fibroblast cells) intracranially
in the immunocompromised mice. CED was achieved by
inserting a cannula into the brain tumor site, which in
turn was connected to a subcutaneous osmotic pump
delivering the immunotoxin into the tumor microenviron-
ment. The antitumor efficacy was evaluated by Kaplan-
Meier survival analysis.
Results
In the orthotopic brain tumor models of 43, NR6M, and
D270MG, D2C7-IT therapy via CED significantly pro-
longed the median survival time (MST) of the treatment
group by about 1 month (P=0.0010), 1 week (P=0.0074),
and over 1 month (P=0.0061), respectively, compared
with that of vehicle or negative control groups (Table 1,
Figure 1).
Conclusion
In the orthotopic brain tumor mouse models, the D2C7-
IT therapy via CED exhibited a robust therapeutic
potential in treating brain tumors expressing EGFRwt,
EGFRvIII, and both EGFRwt and EGFRvIII.
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Figure 1 Kaplan-Meier survival curves of different brain tumor models and the immunotoxin killing paradigm
Table 1 Comparison of MST among different groups in
three xenograft mouse models
(Day) Vehicle P588 D2C7 Log-rank test
43 MST 14 15 43.5* 0.0010
NR6M MST 25 25 32 0.0074
D270MG MST 26 19.5 64** 0.0061
*Last 4 mice were euthanized on Day 90;
**Last 8 mice were euthanized on Day 64.
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